Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB Biogen Inc. daily Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E17.18 EPS (ttm)16.28 Insider Own0.10% Shs Outstand218.90M Perf Week5.83%
Market Cap61.23B Forward P/E13.93 EPS next Y20.08 Insider Trans-1.78% Shs Float218.79M Perf Month-0.71%
Income3.70B PEG1.82 EPS next Q4.66 Inst Own88.50% Short Float0.89% Perf Quarter6.61%
Sales10.94B P/S5.60 EPS this Y24.00% Inst Trans-0.76% Short Ratio1.21 Perf Half Y-4.94%
Book/sh47.18 P/B5.93 EPS next Y6.63% ROA19.00% Target Price345.50 Perf Year-30.58%
Cash/sh16.38 P/C17.08 EPS next 5Y9.45% ROE34.50% 52W Range242.07 - 420.99 Perf YTD-8.70%
Dividend- P/FCF18.70 EPS past 5Y31.30% ROI23.50% 52W High-33.56% Beta0.84
Dividend %- Quick Ratio2.20 Sales past 5Y17.90% Gross Margin88.70% 52W Low15.55% ATR6.60
Employees7350 Current Ratio2.60 Sales Q/Q6.70% Oper. Margin47.10% RSI (14)61.78 Volatility2.66% 2.35%
OptionableYes Debt/Eq0.63 EPS Q/Q26.80% Profit Margin33.80% Rel Volume1.12 Prev Close272.94
ShortableYes LT Debt/Eq0.63 EarningsApr 21 BMO Payout0.00% Avg Volume1.61M Price279.70
Recom2.10 SMA204.28% SMA505.11% SMA200-0.11% Volume1,796,308 Change2.48%
Feb-25-16Initiated Citigroup Buy $345
Jan-20-16Initiated Credit Suisse Neutral
Jan-07-16Initiated Standpoint Research Buy $360
Dec-04-15Resumed Wells Fargo Outperform
Oct-22-15Reiterated H.C. Wainwright Buy $380 → $360
Sep-09-15Initiated Jefferies Buy
Sep-01-15Initiated Raymond James Strong Buy $400
Aug-11-15Initiated H.C. Wainwright Buy $380
Jul-27-15Upgrade Bernstein Mkt Perform → Outperform $436 → $385
Jul-27-15Reiterated RBC Capital Mkts Outperform $525 → $450
Jul-27-15Reiterated Argus Buy $450 → $360
Jul-27-15Downgrade Robert W. Baird Outperform → Neutral $480 → $316
Jul-24-15Downgrade BMO Capital Markets Outperform → Market Perform $511 → $360
Jul-22-15Downgrade Piper Jaffray Overweight → Neutral
Jul-14-15Upgrade BofA/Merrill Neutral → Buy
Jun-11-15Reiterated Leerink Partners Outperform $532 → $512
Jun-09-15Initiated Guggenheim Neutral
Apr-27-15Reiterated UBS Neutral $350 → $422
Apr-27-15Reiterated Argus Buy $440 → $450
Mar-23-15Downgrade Stifel Buy → Hold
May-25-16 02:35PM  Street Talk: BIIB, WDC & more
08:20AM  Short Sellers Grow More Selective on Major Biotechs at 24/7 Wall St.
May-24-16 01:33PM  Samsung Has a Best-Selling American Drug in Its Crosshairs at Fortune
09:04AM  The Best Buys in Biopharma Today at Motley Fool
May-23-16 12:25PM  Biotech: The Next Pricing Controversy? at Barrons.com
05:55AM  A Rudderless Market
May-20-16 12:36PM  J&J is Worth as Much as Gilead, Biogen, Mylan, Celgene and Teva Combined. It's Time to Sell. at Barrons.com
09:06AM  Pfizer, Biogen Can Fancy Acadia for Takeover
May-19-16 04:01PM  Biogen Announces Webcast of Virtual Annual Meeting of Stockholders Business Wire
May-17-16 08:28AM  Biogen, Inc. breached its 50 day moving average in a Bullish Manner : BIIB-US : May 17, 2016
May-16-16 04:04PM  Biogen (BIIB) Stock Closed Higher on Penn Collaboration at TheStreet
01:51PM  Biogen signs licensing deal for Penn gene therapy technology at bizjournals.com
01:10PM  Big Biotech: What's the Worst Case Scenario? at Barrons.com
10:58AM  Biogen plans to launch gene therapy and gene editing collaboration with University of Pennsylvania at MarketWatch
10:58AM  Biogen plans to launch gene therapy and gene editing collaboration with University of Pennsylvania at MarketWatch
07:00AM  Biogen Announces Collaboration with University of Pennsylvania on Multiple Gene Therapy Programs Business Wire
May-13-16 01:30PM  Big Pharma Innovation in Small Places at Fortune
06:39AM  Sell These 5 Stocks Now Before It's Too Late at TheStreet
02:47AM  Alprolix® (rFIXFc) Approved in the EU for the Treatment of Haemophilia B Business Wire
May-12-16 08:20AM  4 Large Cap Growth Stocks to Buy With Incredible 10-Year Track Records at 24/7 Wall St.
May-11-16 01:17PM  Understanding Amgens Analyst Recommendations in 2016 Market Realist
08:15AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
May-10-16 02:54PM  Ionis Pharmaceuticals Inc Is Burning Partners' Cash (Thank Goodness There's Lots of It) at Motley Fool
01:05AM  Biogen Witnessed Strong Growth in Net Profit Margins in 1Q16 Market Realist
May-09-16 02:57PM  ETFs with exposure to Biogen, Inc. : May 9, 2016 at Capital Cube
08:00AM  5 Large-Cap Growth Mutual Funds for Bull and Bear Markets (MFEGX, HRCPX) at Investopedia
May-08-16 03:02PM  The Revolutionary Multiple Sclerosis Drug You've Never Heard Of at Motley Fool
May-07-16 04:00PM  Biotech Is Ripe for M&A: Analysts at TheStreet
May-06-16 05:30PM  Biotech Stocks Are Down 25% So Far This Year at Fortune
May-05-16 11:22AM  Acadia Drug Approval May Entice Biogen, Teva as Buyers The Deal Pipeline
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Gilead, Celgene, Medivation and Biogen Zacks
09:01AM  Biogen, Inc. breached its 50 day moving average in a Bearish Manner : BIIB-US : May 5, 2016 at Capital Cube
May-04-16 03:41PM  Better Buy: Gilead Sciences vs. Biogen at Motley Fool
03:05PM  Here are the local biotechs devoting the biggest chunk of their budget to R&D at American City Business Journals
01:11PM  Biotech Stock Roundup: Amgen Impresses, Gilead Disappoints in Q1, Biogen to Spin Off Hemophilia Zacks
09:30AM  Why Biogen Is Hiving Off Its Hemophilia Business at Investopedia
May-03-16 10:22PM  Biogen to Spin Off Hemophilia Business at The Wall Street Journal
04:34PM  [$$] Biogen to Spin Off Hemophilia Unit at The Wall Street Journal
03:50PM  These Biopharma Companies Are the Worlds Top Shareholder Value Creators at Fortune
03:25PM  Biogen Inc. -- Moody's: Biogen's hemophilia spin-off is credit negative at Moody's
03:14PM  Will Biogen's Hemophilia Spinoff Hurt the Company Long Term? at TheStreet
01:33PM  Biogen Is All In On Brains at Bloomberg
11:30AM  Einhorn's bet on Yelp; Pfizer posts 20% jump; GM's sales miss Yahoo Finance
11:19AM  Biogen to spin off hemophilia drugs and focus on core neuro business Reuters
10:49AM  Biogen's Hemophilia Spin: Prelude to a Takeover? at Barrons.com
10:27AM  Biogen Spinning Off Hemophilia Business As Competition Heats Up at Investor's Business Daily
10:19AM  Term Sheet Tuesday, May 3 at Fortune
08:59AM  How to Trade 5 Biotech Stocks After a Fall -- Plus Jim Cramer's Take at TheStreet
08:42AM  Biogen Plans To Spin-Off Its Hemophilia Unit As Publicly Traded Firm Benzinga
08:03AM  Forget Bluebird Bio, Inc.: These 3 Stocks Are Better Buys at Motley Fool
07:50AM  Early movers: PFE, BIIB, TAP, CVS, MNK, IMS, CLX, COST & more at CNBC
07:50AM  Biogen to spin off hemophilia business into public company at MarketWatch
07:43AM  Biogen to spin off hemophilia drug business into a public company Reuters
07:33AM  BIOGEN INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
07:30AM  Biogen Announces Intent to Spin off Its Hemophilia Business Business Wire
May-02-16 03:22PM  Biotech ETFs Sink on Mixed Q1 Results Zacks
Apr-30-16 12:01AM  [$$] The Barron's 500: AmerisourceBergen Ranks No. 1 at Barrons.com
Apr-29-16 04:10PM  Apple Drives Selloff on April's Last Trading Day at TheStreet
02:42PM  Stocks Sell Off in Final Trading Day of April at TheStreet
01:14PM  What Are Analysts Saying About Q1 At Biotech's Big 4? Amgen, Biogen, Celgene, Gilead at Forbes
11:07AM  BIOGEN INC. Files SEC form 8-K, Other Events EDGAR Online
07:39AM  Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA (Daclizumab) for Treatment of Multiple Sclerosis Business Wire
07:26AM  Biogen, AbbVie multiple sclerosis drug wins EU green light Reuters
Apr-28-16 01:02PM  ETFs with exposure to Biogen, Inc. : April 28, 2016 at Capital Cube
12:00PM  Biotech Boom May Continue Through Earnings Season Benzinga
10:06AM  Tysabri Reports Strong Patient Growth in 1Q16 Market Realist
09:30AM  The Zacks Analyst Blog Highlights: Biogen, Sarepta, Catalyst Pharmaceuticals, AbbVie and Gilead Zacks
Apr-27-16 04:07PM  Biotech Stock Roundup: Biogen Tops on Q1 Earnings, Sarepta, Catalyst Plunge on Regulatory News Zacks
01:04PM  BIOGEN INC. Financials EDGAR Online Financials
10:49AM  Why Biogen Is Poaching This Pfizer Exec to Head Up Its R&D Shop at Fortune
09:23AM  Biogen, Inc. :BIIB-US: Earnings Analysis: Q1, 2016 By the Numbers at Capital Cube
09:15AM  Biogen Appoints Michael Ehlers Executive Vice President, Research and Development Business Wire
09:05AM  4 Biotech Stocks Reporting on Apr 28: AMGN, GILD, ALXN, CELG Zacks
08:10AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
Apr-26-16 12:07PM  Biogens Hemophilia Drugs Continue to Capture Market Share in 1Q16 Market Realist
11:40AM  Biogen Is Ready to Rise After a 10-Month Downward Spiral at TheStreet
Apr-25-16 11:57AM  Tecfidera Continues to Be Key Revenue Driver for Biogen in 1Q16 Market Realist
11:56AM  How Did Biogen Perform in 1Q16? Market Realist
Apr-24-16 12:59PM  5 Trade Ideas for Monday: Biogen, KKR, Web.com, Zillow and ON Semi Yahoo Finance Contributors
Apr-22-16 06:17PM  Still The Greatest Growth Company Wall Street Has Never Heard Of Yahoo Finance Contributors
06:00PM  Biogen Inc Earnings Explode Higher, Revenue Not So Much at Motley Fool
12:57PM  Leerink Lowers Biogen Price Target Ahead Of M&A Potential at Barrons.com
12:06PM  Here Are the Fortune 500s Highest Paid Tech Execs at Fortune
Apr-21-16 05:25PM  [$$] Biogen: Biotech Bargain at Barrons.com +5.16%
12:57PM  Key Morning Earnings for April 21: BIIB, GM, UA, VZ Zacks
12:17PM  7 Stocks, 7 trades: YUM, GM, BIIB & more CNBC
12:04PM  Heres Why Biogens Shares Are Climbing Today at Fortune
11:55AM  Drop in Biogens research costs not a deliberate effort, says CEO at American City Business Journals
11:37AM  Edited Transcript of BIIB earnings conference call or presentation 21-Apr-16 12:30pm GMT Thomson Reuters StreetEvents
11:22AM  Cost cutting helps Biogen top Wall Street estimates for quarter Reuters
10:33AM  Biogen Q1 Earnings Beat Estimates, But Sales Miss; Stock Climbs at Investor's Business Daily
10:23AM  New Earnings, Same Old Biogen at Barrons.com
10:17AM  Biogen (BIIB) Tops on Q1 Earnings, Slight Revenue Miss Zacks
08:49AM  Biogen (BIIB) Beats on 1Q Earnings by a Wide Margin Zacks
07:49AM  Biogen beats 1Q profit forecasts AP
07:27AM  BIOGEN INC. Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
07:27AM  Biogen first-quarter sales rise 6.7 percent Reuters
07:15AM  Biogen Reports First Quarter 2016 Revenues of $2.7 Billion Business Wire
07:07AM  Q1 2016 Biogen Inc Earnings Release - Before Market Open CCBN
Apr-20-16 03:10PM  Why It May Be Time to Get Bullish on Biotech Yahoo Finance Contributors
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. It offers TECFIDERA, AVONEX, and PLEGRIDY to treat relapsing forms of multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn's disease; and FAMPYRA to improve walking ability for patients with MS. The company also provides ELOCTATE to treat adults and children with hemophilia A for control of bleeding episodes; ALPROLIX to treat adults and children with hemophilia B for control of bleeding episodes; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat plaque psoriasis. The company's products in Phase III development stage comprise ZINBRYTA, a monoclonal antibody for the treatment of relapsing-remitting MS; Aducanumab for Alzheimer's disease; and ISIS-SMNRx for spinal muscular atrophy. Its Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Amiselimod for multiple autoimmune indications; BAN2401 and E2609 for Alzheimer's disease; Raxatrigine for trigeminal neuralgia; rAAV-XLRS for X-linked juvenile retinoschisis; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise Dapirolizumab pegol for systemic lupus erythematosus (SLE); ISIS DMPK for myotonic dystrophy; Anti-BDCA2 for SLE; Anti-alpha-synuclein for Parkinson's disease; and BIIB063 for sjogren's syndrome. The company has a strategic research collaboration with Ionis Pharmaceuticals, Inc. It offers products primarily through its own sales force, marketing groups, and third parties worldwide. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCANGOS GEORGE AChief Executive OfficerMay 02Sale274.74487133,79859,790May 04 05:03 PM
Koppel AdamEVP, Strategy and Bus. Dev.Apr 06Sale275.0010228,0501,848Apr 07 05:03 PM
SCANGOS GEORGE AChief Executive OfficerApr 06Sale280.0015743,96060,277Apr 07 05:01 PM
Artavanis-Tsakonas SpyridonEVP, Chief Scientific OfficerApr 02Option Exercise0.0097503,609Apr 05 05:06 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale258.83487126,05060,434Apr 05 05:02 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 25Sale261.9018347,9287,990Feb 26 04:08 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 23Option Exercise0.00636032,140Feb 25 05:05 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 23Option Exercise0.0057908,599Feb 25 04:59 PM
DiPietro KennethEVP Human ResourcesFeb 23Option Exercise0.0063604,237Feb 25 05:01 PM
Koppel AdamEVP, Strategy and Bus. Dev.Feb 23Option Exercise0.0030101,963Feb 25 05:02 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 23Option Exercise0.006602,709Feb 25 05:09 PM
Clancy Paul JExecutive VP and CFOFeb 23Option Exercise0.00579027,143Feb 25 05:13 PM
SCANGOS GEORGE AChief Executive OfficerFeb 23Option Exercise0.002,964062,812Feb 25 04:51 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 17Sale256.16722184,9487,990Feb 19 04:18 PM
SCANGOS GEORGE AChief Executive OfficerFeb 17Sale256.16487124,75059,848Feb 19 04:20 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.003,31604,466Feb 17 06:00 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.003,859027,768Feb 17 05:53 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.001,05702,692Feb 17 05:54 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,274052,364Feb 10 04:19 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 09Sale246.54852210,0527,740Feb 10 04:17 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 08Option Exercise0.001,27809,018Feb 10 04:17 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,026029,666Feb 09 04:51 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,70907,030Feb 09 04:48 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise273.452,466674,3282,466Feb 02 04:05 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratDec 04Sale277.00441122,1577,740Dec 07 04:20 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsDec 02Sale289.144813,8797,875Dec 03 04:19 PM
DENNER ALEXANDER JDirectorOct 23Buy276.77100,00027,677,000310,000Oct 26 07:03 PM
DENNER ALEXANDER JDirectorOct 22Buy277.80210,00058,338,000210,000Oct 26 07:03 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsOct 05Sale291.4326978,3958,094Oct 06 04:40 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsOct 02Sale283.38417118,1698,363Oct 05 04:10 PM
Karaboutis AdrianaEVP, Tech. and Bus. SolutionsOct 01Option Exercise0.001,939010,446Oct 05 04:10 PM
PAPADOPOULOS STELIOSDirectorJul 27Buy304.8810,0003,048,7755,000Jul 27 05:03 PM
Posner Brian SDirectorJun 22Sale415.00470195,0505,275Jun 23 04:14 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentJun 19Sale410.003,8411,574,81011,817Jun 22 04:15 PM
Posner Brian SDirectorJun 15Sale386.64400154,6565,745Jun 16 06:54 PM
Koppel AdamSVP, Chief Strategy OfficerJun 02Option Exercise0.002,38402,514Jun 04 05:49 PM
SCANGOS GEORGE AChief Executive OfficerJun 01Sale398.871,362543,26141,090Jun 02 04:10 PM